As an­ti-in­flam­ma­to­ry space heats up, Pfiz­er spins JAK, TYK2 drugs in­to new start­up

Hav­ing bet heav­i­ly on JAK in­hibitors — putting to­geth­er a port­fo­lio an­chored by Xel­janz and now Cib­in­qo — Pfiz­er is get­ting some help to de­vel­op its next such can­di­date.

But we don’t know who the part­ner is just yet.

In pre­pared re­marks dur­ing Pfiz­er’s Q3 earn­ings call, CEO Al­bert Bourla re­vealed to in­vestors that the com­pa­ny has ex­clu­sive­ly li­censed bre­poc­i­tinib, a Phase II dual JAK/TYK2 in­hibitor, to “a new com­pa­ny formed in col­lab­o­ra­tion with a part­ner that has a proven track record in late-stage in­flam­ma­tion and im­munol­o­gy drug de­vel­op­ment.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER